Aurobindo launches generic Advair Diskus in US market
- Lannett Company LLC launched generic Advair Diskus in the US on August 31, 2026
- Product available in 100/50 mcg and 250/50 mcg strengths
- First commercial inhalation product from Aurobindo's pipeline
- Targets asthma and COPD patients with generic alternative
*this image is generated using AI for illustrative purposes only.
Aurobindo Pharma 's subsidiary Lannett Company LLC has launched a generic version of Advair Diskus in the US on August 31, 2026. The product is available in 100/50 mcg and 250/50 mcg strengths, marking the first commercial inhalation product from the company's pipeline.
Milestone in inhalation therapeutics
The launch represents a significant step for Lannett Company LLC as it brings its first inhalation product to the US market. Advair Diskus is a widely used combination inhaler prescribed for the management of asthma and chronic obstructive pulmonary disease (COPD), and the introduction of a generic version expands patient access to this therapy.
Product and pipeline context
The following table summarises the key details of this product launch:
| Parameter | Details |
|---|---|
| Company | Lannett Company LLC (subsidiary of Aurobindo Pharma) |
| Product | Generic Advair Diskus |
| Strengths | 100/50 mcg and 250/50 mcg |
| Market | United States |
| Therapeutic area | Asthma and COPD |
| Pipeline significance | First product from inhalation pipeline |
The launch underscores Aurobindo Pharma's strategic focus on building a presence in the complex inhalation segment, which is considered a high-barrier, high-value category within the US generics market.
Historical Stock Returns for Aurobindo Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.27% | +2.77% | +7.55% | +36.53% | +62.35% | 0.0% |
How is the launch of generic Advair Diskus expected to impact Teva Pharmaceutical's revenue and market share in the US respiratory generics segment?
What regulatory or manufacturing challenges might Aurobindo Pharma face when scaling up production for complex inhalation devices compared to oral solids?
Will this successful entry into inhalation therapeutics accelerate Aurobindo's pipeline development for other high-barrier respiratory products?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
